The Clorox Company (CLX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Oct, 2026Executive summary
FY26 transition year: completed U.S. ERP implementation, acquired GOJO and acquired full ownership of the Glad bags and wraps business; FY27 priorities include profitable growth, innovation and margin recovery.
Net sales were $6.7B, down 5% YoY; net earnings attributable to Clorox were $587M, down 28%, and gross margin was 42.3%, down 290 bps.
Linda Rendle requested a CEO search for health reasons; she remains Chair and CEO until a successor is appointed and will serve in an advisory role afterward.
Voting matters and shareholder proposals
Annual meeting set for November 18, 2026, virtually; agenda: elect 10 directors, approve executive compensation on an advisory basis and ratify Ernst & Young LLP for FY27.
Board recommends FOR all 10 nominees, say-on-pay and auditor ratification; 2025 say-on-pay received ~91% of votes cast in favor.
Director elections require a majority of votes cast; proposals 2 and 3 require a majority of voting power present and entitled to vote. Abstentions count against proposals 2 and 3.
Rule 14a-8 proposals for the 2027 meeting are due June 9, 2027; proxy-access notices are due May 10–June 9, 2027, subject to eligibility requirements.
Board of directors and corporate governance
Ten nominees stand for election through the 2027 annual meeting; A.D. David Mackay will not seek re-election, reducing the Board from 11 to 10 directors.
Nine of 10 nominees are independent; average nominee tenure is 6.3 years, and five new independent directors joined since 2022.
Independent CEO Search Committee, chaired by Lead Independent Director Matthew Shattock and including the three independent committee chairs, leads the CEO search and reports regularly to the full Board.
In FY27, an independent third-party facilitator is planned for annual Board, committee and director evaluations.
Board structure combines Chair and CEO with a strong lead independent director and independent committee chairs; all standing committees consist solely of independent directors.
Latest events from The Clorox Company
- Board seeks support for director slate, say-on-pay and auditor ratification.CLX
Proxy filing - Innovation and health & hygiene drive growth amid leadership transition and inflationary pressures.CLX
Boston Global Staples Conference 2026 - FY27 outlook: double-digit sales growth, higher EPS, and GOJO and ERP integration benefits.CLX
Q4 2026 - ERP stabilization, innovation, and GOJO integration drive growth amid leadership transition.CLX
23rd annual dbAccess Global Consumer Conference - Q2 FY2026 sales and earnings declined, with major acquisitions and ongoing cost pressures.CLX
Q2 2026 - $2.25B acquisition expands health & hygiene leadership, driving $50M in synergies.CLX
M&A announcement - Net sales fell 19% and gross margin dropped to 41.7% amid ERP transition impacts.CLX
Q1 2026 - FY25 margin and EPS growth driven by ERP shipments, with FY26 headwinds as benefits reverse.CLX
Q4 2025 - Digital transformation and IGNITE strategy accelerate growth, margin expansion, and innovation.CLX
Consumer Analyst Group of New York Conference 2025